Welichem Reports Positive Results From Phase IIa Atopic Dermatitis Trial
Welichem Biotech, a development-stage biopharmaceutical company, has announced positive results from its Phase IIa clinical trial of its drug candidate, WBI-1001, a new, non-steroid, topical cream treatment for atopic dermatitis.
In the trial, two concentrations (0.5% and 1%) of WBI-1001 were tested against the placebo. Both WBI-1001 cream concentrations were superior to placebo in deceasing atopic dermatitis (AD) and showed an excellent safety profile.
This clinical Phase IIa trial for WBI-1001 was a randomized, double-blind, placebo-controlled study conducted in Montreal with the objectives of evaluating the safety and efficacy of the cream on topically treated patients. A total of 36 patients with mild-to-moderate AD were treated with 0.5% or 1% of WBI-1001 cream or placebo twice daily for 28 days.
No serious side effects were reported in any of the groups and no patient dropped out due to adverse side effects of the treatment. All primary efficacy indices measured efficacy positively and WBI-1001 was significantly more efficacious than placebo at one or both treatment doses for all indices at day 28, the end of the treatment. Welichem plans to conduct further clinical trials for WBI-1001 in 2009.
Genhui Chen, CEO of Welichem, said: “We are very pleased to be able to present such positive results from the company’s clinical trial on atopic dermatitis. AD is a major unmet medical indication, and these positive results are of significance for our overall strategy of developing WBI-1001 for the treatment of this disease and additional conditions.”